BrdU Positive Cells Induced in a Genetic Mouse Model of Glaucoma

Area of Science:

• Neuroscience
• Ophthalmology
• Pharmacology

Background:

• Glaucoma leads to retinal ganglion cell (RGC) loss.
• Selective α7 nicotinic acetylcholine receptor agonists may promote RGC neurogenesis.
• PNU-282987 has previously shown neurogenesis-inducing properties in wild-type rodents.

Purpose of the Study:

• To investigate if PNU-282987 can reverse RGC loss in a genetic glaucoma mouse model (DBA/2J).
• To evaluate both short-term and chronic early treatment effects of PNU-282987 on RGCs.

Main Methods:

• DBA/2J mice (3, 6, and 10 months old) received PNU-282987 or BrdU eye drops for short-term or chronic early treatment.
• Retinal ganglion cell counts were assessed via immunostaining.
• Intraocular pressure (IOP) was monitored weekly.

Main Results:

• DBA/2J mice showed a typical 29% RGC loss by 10 months with increased IOP.
• A two-week PNU-282987 treatment significantly increased RGCs by 21% across all ages.
• Chronic early PNU-282987 treatment also significantly increased RGCs; acute early treatment had no effect.
• PNU-282987 did not affect IOP.

Conclusions:

• PNU-282987 treatment, both short-term (2 weeks) and chronic, effectively increased RGC numbers in the DBA/2J glaucoma model.
• The drug counteracted the genetic glaucoma-induced RGC loss without altering IOP.
• PNU-282987 shows promise as a therapeutic agent for degenerative retinal diseases.